S10260 • 2025

Adds CLN2, MPS IVA, MPS VI, MPS VII and Fabry diseases to the newborn screening panel for New York state

Active

The official status still shows this bill as active or still awaiting another formal step.

Sponsor: Lea Webb
Last action: 2026-05-08
Official status: In Senate Committee
Effective date: Not listed

Plain English Breakdown

Using official source text because the generated explanation was unavailable or could not be confirmed against the official bill text.

Adds CLN2, MPS IVA, MPS VI, MPS VII and Fabry diseases to the newborn screening panel for New York state

Adds CLN2, MPS IVA, MPS VI, MPS VII and Fabry diseases to the newborn screening panel for New York state Adds CLN2, MPS IVA, MPS VI, MPS VII and Fabry diseases to the newborn screening panel for New York state; requires tests be made available within twelve months.

What This Bill Does

Adds CLN2, MPS IVA, MPS VI, MPS VII and Fabry diseases to the newborn screening panel for New York state Adds CLN2, MPS IVA, MPS VI, MPS VII and Fabry diseases to the newborn screening panel for New York state; requires tests be made available within twelve months.

Limits and Unknowns

This entry is temporarily using official source text because the generated explanation could not be confirmed against the official bill text during the last sync.

Bill History

2026-05-08 Senate
REFERRED TO HEALTH

Official Summary Text

Adds CLN2, MPS IVA, MPS VI, MPS VII and Fabry diseases to the newborn screening panel for New York state
Adds CLN2, MPS IVA, MPS VI, MPS VII and Fabry diseases to the newborn screening panel for New York state; requires tests be made available within twelve months.

Current Bill Text

Read the full stored bill text

S T A T E   O F   N E W   Y O R K
        ________________________________________________________________________

                                          10260

                                    I N  S E N A T E

                                       May 8, 2026
                                       ___________

        Introduced  by  Sen.  WEBB  --  read twice and ordered printed, and when
          printed to be committed to the Committee on Health

        AN ACT to amend the public health law, in relation to newborn  screening
          for CLN2, MPS IVA, MPS VI, MPS VII and Fabry diseases

          THE  PEOPLE OF THE STATE OF NEW YORK, REPRESENTED IN SENATE AND ASSEM-
        BLY, DO ENACT AS FOLLOWS:

     1    Section 1. Subdivision 1 of section 2500-a of the public health law is
     2  amended by adding five new paragraphs (l), (m), (n), (o) and (p) to read
     3  as follows:
     4    (L) LATE-INFANTILE NEURONAL CEROID LIPOFUSCINOSIS TYPE 2 (CLN2).
     5    (M) MUCOPOLYSACCHARIDOSIS TYPE IVA (MPS IVA).
     6    (N) MUCOPOLYSACCHARIDOSIS TYPE VI (MPS VI).
     7    (O) MUCOPOLYSACCHARIDOSIS TYPE VII (MPS VII).
     8    (P) FABRY.
     9    § 2. Section 2500-a of the public health law is amended  by  adding  a
    10  new subdivision 4 to read as follows:
    11    4.  THE  COMMISSIONER  SHALL  ENSURE  TESTS ARE MADE AVAILABLE FOR ALL
    12  DISEASES AND CONDITIONS DESIGNATED PURSUANT TO PARAGRAPHS (L), (M), (N),
    13  (O) AND (P) OF SUBDIVISION ONE OF THIS SECTION WITHIN TWELVE  MONTHS  OF
    14  THE EFFECTIVE DATE OF SUCH PARAGRAPHS.
    15    § 3. This act shall take effect immediately.





         EXPLANATION--Matter in ITALICS (underscored) is new; matter in brackets
                              [ ] is old law to be omitted.
                                                                   LBD15047-03-6